Anhui Anke Biotechnology (Group) Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Lihua Song

Chief Executive Officer (CEO)

CN¥2.7m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	31.5yrs
Participación del CEO	26.6%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	3.4yrs

Actualizaciones recientes de la dirección

Recent updates

Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price Is Matching Sentiment Around Its Earnings

Sep 25

Anhui Anke Biotechnology (Group) (SZSE:300009) Will Pay A Dividend Of CN¥0.25

May 23

Earnings Working Against Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price

Mar 01

CEO

Lihua Song (67 yo)

31.5yrs

Permanencia

CN¥2,712,000

Compensación

Mr. Song Lihua serves as the Chairman of the Board and President at Anhui Anke Biotechnology (Group) Co., Ltd and its Director since May 1, 1993.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lihua Song	Chairman of Board of Directors & President	no data	CN¥2.71m	26.57% CN¥ 3.9b
Chenghao Hu	Financial Director	less than a year	CN¥438.70k	0.0024% CN¥ 349.7k
Jian Ping Yao	Executive President	no data	CN¥857.00k	0.40% CN¥ 59.2m
Hai Sheng	Senior Vice President	no data	CN¥1.11m	0.23% CN¥ 33.6m
Hui Zhao	Senior VP & Director	no data	CN¥651.00k	0.61% CN¥ 89.5m
Chunyan Lu	Vice President	less than a year	CN¥506.00k	0.020% CN¥ 2.9m
Yuanyuan Zhou	VP & Director	2.4yrs	CN¥635.00k	0.13% CN¥ 19.3m
Hongyi Yao	Vice President	1.7yrs	CN¥531.00k	0.048% CN¥ 7.0m
Xueke Bao	Vice President	less than a year	CN¥1.10m	0.025% CN¥ 3.6m
Yinghui Dou	Vice President	1.9yrs	CN¥687.00k	0.024% CN¥ 3.5m
Tawei Chou	Vice President	less than a year	CN¥887.00k	0.0087% CN¥ 1.3m
Kun Li	Secretary of the Board & Director	4.9yrs	CN¥469.00k	0.022% CN¥ 3.2m

1.3yrs

Permanencia media

49.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300009 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lihua Song	Chairman of Board of Directors & President	31.5yrs	CN¥2.71m	26.57% CN¥ 3.9b
Hui Zhao	Senior VP & Director	17.6yrs	CN¥651.00k	0.61% CN¥ 89.5m
Yuanyuan Zhou	VP & Director	1.9yrs	CN¥635.00k	0.13% CN¥ 19.3m
Kun Li	Secretary of the Board & Director	1.9yrs	CN¥469.00k	0.022% CN¥ 3.2m
Xian Yu Du	Director	less than a year	CN¥72.00k	0.039% CN¥ 5.7m
Li Ming Song	Vice Chairman of the Board	21.3yrs	CN¥976.00k	6.87% CN¥ 1.0b
Yong Bin Wang	Director	11yrs	CN¥501.00k	0.072% CN¥ 10.5m
Guang Fu Liu	Independent Director	4.9yrs	CN¥75.00k	sin datos
Wei Dong Zhu	Independence Director	4.9yrs	CN¥75.00k	sin datos
Junpei Jiang	Director	1.9yrs	CN¥501.50k	0.058% CN¥ 8.5m
Feihu Chen	Independent Director	1.9yrs	CN¥75.00k	sin datos
Xiaoping Geng	Independent Director	1.9yrs	CN¥75.00k	sin datos

3.4yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 300009 se considera experimentada (3.4 años de antigüedad promedio).

Anhui Anke Biotechnology (Group) Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024

Less than half of directors are independent

Anhui Anke Biotechnology (Group) Co., Ltd. Announces Board Elections

Less than half of directors are independent

Less than half of directors are independent

Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 20, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.15 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 15%

Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price Is Matching Sentiment Around Its Earnings

Consensus revenue estimates decrease by 18%, EPS upgraded

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)

Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Anhui Anke Biotechnology (Group) (SZSE:300009) Will Pay A Dividend Of CN¥0.25

Dividend of CN¥0.25 announced

First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 1Q 2023)

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Working Against Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price

Investor sentiment improves as stock rises 20%

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022)

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.10 in 2Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Anhui Anke Biotechnology (Group) Co., Ltd. Announces Board Elections

Investor sentiment improved over the past week

Price target decreased to CN¥18.92

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.075 in 2Q 2021)

Anhui Anke Biotechnology (Group) Co., Ltd. Announces Cash Dividend for the Year 2021, Payable on 13 May 2022

Price target decreased to CN¥18.92

First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.075 in 1Q 2021)

Less than half of directors are independent

Anhui Anke Biotechnology (Group) Co., Ltd. Approves Profit Distribution

Full year 2021 earnings: EPS and revenues miss analyst expectations

Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 20, 2022

Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE:300009) announces an Equity Buyback for CNY 60 million worth of its shares.

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.075 (vs CN¥0.049 in 2Q 2020)

Investor sentiment deteriorated over the past week

Anhui Anke Biotechnology (Group) Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented for 2020 (A Shares), Payable on 14 May 2021

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.062 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.092 in FY 2019)

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2020 Results on Apr 08, 2021

New 90-day low: CN¥13.69

New 90-day low: CN¥14.64

New 90-day low: CN¥14.71

New 90-day low: CN¥15.69

Third quarter earnings released

Earnings released

New 90-day high - CN¥20.86

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad